
Francis Rooney sold Novozymes AS (PINK: NVZMY)
Francis Rooney (R-FL), a U.S. Representative, has disclosed 1 trade in Novozymes AS (NVZMY) since 2017, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Francis Rooney sold $1,000 - $15,000 of Novozymes AS (PINK: NVZMY) on April 19, 2017. Since that trade, NVZMY is up +82.73% against the S&P 500 up +266.41%, an outperformance of -183.68%.
Data updated
Francis Rooney's NVZMY trades vs the price
NVZMY is up +82.73% since Francis Rooney sold on April 19, 2017, versus +266.41% for the S&P 500.
Performance since this trade
All Francis Rooney NVZMY trades
Francis Rooney & NVZMY trading FAQ
Is it legal for Francis Rooney to trade Novozymes AS (NVZMY) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Novozymes AS (NVZMY), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Francis Rooney sell NVZMY?
Francis Rooney disclosed a sale of $1,000 - $15,000 of Novozymes AS (NVZMY) on April 19, 2017, according to public STOCK Act filings.
How has NVZMY performed since Francis Rooney's trade?
Since Francis Rooney sold NVZMY on April 19, 2017, the stock is up +82.73%, versus +266.41% for the S&P 500 over the same period, an outperformance of -183.68%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional NVZMY trades?
Quantellect tracks every disclosed congressional trade in Novozymes AS (NVZMY) on the Novozymes AS congressional trading page, which aggregates filings across all members of Congress.
Francis Rooney's NVZMY tradesAll congressional filings for Novozymes ASFrancis Rooney's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.

